RxDoctor Payments Data

Lauren Jackson, MD

Family Medicine · Augusta, GANPI 1861874380

Payments from drug & device makers

$7,417in general payments, 2019–2025

Across 424 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$857
  • AstraZeneca$711
  • Pfizer$475
  • Lilly USA, LLC$459
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$7,411100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,417 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$45,540
Medicare patients
119
Services billed
715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide55$71,680
JardianceEmpagliflozin54$70,230
TrulicityDulaglutide30$48,888
OzempicSemaglutide27$45,494
FarxigaDapagliflozin Propanediol39$35,294
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$35,168
EliquisApixaban38$31,846
RybelsusSemaglutide11$25,941
LinzessLinaclotide23$19,666
Tresiba Flextouch U-100Insulin Degludec26$19,338
JanuviaSitagliptin Phosphate18$17,919
MyrbetriqMirabegron14$10,289
Albuterol Sulfate HfaAlbuterol Sulfate128$4,242
Lidocaine12$4,083
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$3,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$459$120,56885 claims
Novo NordiskOzempic, Rybelsus$1,605$71,43538 claims
Boehringer IngelheimJardiance$262$70,23054 claims
AstraZenecaFarxiga$711$35,29439 claims
GSKTrelegy Ellipta$857$35,16823 claims
PfizerEliquis$475$31,84638 claims
AbbVieLinzess$1,292$19,66623 claims
MerckJanuvia$71$17,91918 claims
Astellas Pharma US IncMyrbetriq$114$10,28914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →